The largest database of trusted experimental protocols

12 protocols using fgf19

1

Measurement of Serum Angiogenic Factors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Serum VEGF, ANG2, FGF19, and FGF21 levels were evaluated using commercial enzyme-linked immunosorbent assays (VEGF, ANG2, and FGF19: R&D Systems, Minneapolis, MN, USA; FGF21: Merck Millipore, Darmstadt, Germany) according to the manufacturers’ protocols [14 (link)].
+ Open protocol
+ Expand
2

Canine Hepatic Progenitor Cell Isolation and Differentiation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Hepatic progenitor cells were isolated from canine liver tissue upon mechanical dissection and subsequent type-II collagenase (Gibco, Landsmeer, the Netherlands) and dispase (Gibco, Landsmeer, the Netherlands) digestion, as described previously [20 (link)]. Expansion medium (EM) conditions, medium changes and split ratio were as described, in detail, in [20 (link)]. Organoid stem cell differentiation towards hepatocytes was induced by the addition of 25 ng/mL BMP7 (Peprotech, Heerhugowaard, the Netherlands) after the last passage in expansion medium. Four days after the last passage, Wnt-conditioned medium, ROCK inhibitor, and Noggin were withdrawn from the medium. Further differentiation was acquired by withdrawal of nicotinamide, R-spondin-1-conditioned medium, and FGF10 six days after the last passage in expansion medium. Finally, BMP7 was continued and 100 ng/mL FGF19 (R&D Systems, Abingdon, UK), 10 µM DAPT (Selleckchem, Huissen, the Netherlands), and 30 µM dexamethasone (Sigma-Aldrich, Zwijndrecht, the Netherlands) were added. This culture was continued for over one week. The lentiviral transduction to supplement COMMD1-deficient organoids with the correct COMMD1 coding sequence was as described previously [20 (link)].
+ Open protocol
+ Expand
3

Cellular Signaling Modulation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were treated with the following reagents at the specified concentrations: glucagon 100 nmol/L (RayBiotech, Peachtree Corners, GA; cat# 228-10549-1); corticosterone 1 μmol/L (Sigma-Aldrich, St Louis, MO; 50-22-6); insulin 1 μmol/L (Biological Industries, Beit HaEmek, Israel; 41-975-100); FGF19 80 ng/mL (R & D, Minneapolis, MN; 969-FG); H-89 20 μmol/L (Sigma-Adlrich; B1427); RU-486 2 μmol/L (Sigma-Aldrich; 84371-65-3); L-cycloserine 300 μmol/L (Sigma-Aldrich; 339-72-0); and AOA 1 mmol/L (Cayman Chemical Company, Ann Arbor, MI; 28298).
+ Open protocol
+ Expand
4

Serum Growth Factor Profiling in Disease

Check if the same lab product or an alternative is used in the 5 most similar protocols
We evaluated serum VEGF-A, VEGF-C, VEGF-D, ANG-2, HGF, EGF, and FGF-19, levels using commercial enzyme-linked immunosorbent assays, according to the manufacturer’s protocols. (ANG-2, FGF-19, HGF, and EGF: R&D Systems, Minneapolis, MN, USA; VEGF-A: Cloud-Clone Crop, Wuhan, China; VEGF-C, VEGF-D: Thermo Fisher Scientific, Waltham, MA, USA).
We analyzed changes in serum growth factors at baseline, as well as the best overall response and progressive disease (PD) points.
+ Open protocol
+ Expand
5

C2C12 Myoblast Differentiation and Treatment

Check if the same lab product or an alternative is used in the 5 most similar protocols
C2C12 mouse myoblasts (ATCC) were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Gibco) containing 4.5 g/L D‐glucose, 10% foetal bovine serum (Gibco) and 1% penicillin‐streptomycin solution (HyClone) in appropriate conditions. When the cells reached 90%‐100% confluence, they were incubated in DMEM containing 2% horse serum (HS, Bioind, Israel) to promote differentiation into myotubes for 5 days. The myotubes were treated with 100 ng/mL FGF19 (R&D) and 0.5 mM PA (Sigma‐Aldrich) for 24 hours. The dissolution method and concentration selection of FGF19 and PA were consistent with our previous study.22
+ Open protocol
+ Expand
6

Authenticating and Culturing Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human cancer cell lines originated from the CCLE [18 (link)] were authenticated by single-nucleotide polymorphism analysis and tested for mycoplasma infection using a PCR-based detection technology (RADIL, University of Missouri, Columbia, MO; now IDEXX Laboratories). All cell lines used were directly thawed from the CCLE collection stock and cultured as previously described [18 (link)] except SW1736 (Creative Bioarray). Cell lines were used within 15 passages of thawing and continuously cultured for less than 6 months. All small molecule inhibitors used were synthesized and structurally verified by NMR and LC/MS according to cited references at Novartis except RMC-4550 (Selleck Chemicals), NSC-87877 (Selleck Chemicals), and IIB-08 (Millipore Sigma). EGF and FGF19 were purchased from R&D Systems.
+ Open protocol
+ Expand
7

Directed Hepatocyte Differentiation from IHCC Organoids

Check if the same lab product or an alternative is used in the 5 most similar protocols
As shown in Fig. 2a, hepatocyte differentiation using IHCC organoids was conducted as described previously27 (link). IHCC organoids were cultured for 7–10 days in EM additionally supplemented with BMP7 (25 ng/ml). Then, the culture medium was changed to differentiation medium (DM) composed of Advanced DMEM/F12 supplemented with Glutamax, 10 mM HEPES, penicillin/streptomycin, 1 × N2 supplement, 1 × B27 supplement, 50 ng/mL EGF, 50 nM gastrin, 25 ng/ml HGF (Peprotech), 100 ng/ml FGF19 (R&D systems), 10 μM DAPT (Sigma-Aldrich), 25 ng/ml BMP7 (Peprotech), and 30 μM dexamethasone (Sigma-Aldrich). DM was changed every 2–3 days for a period of 12 days.
+ Open protocol
+ Expand
8

Hepatocyte Differentiation from Organoids

Check if the same lab product or an alternative is used in the 5 most similar protocols
Differentiation of organoids into hepatocytes was induced as previously described18 (link). Briefly, after amplification organoids were first cultured in EM media supplemented by BMP7 (25 ng/ml) for 7–10 days, then split and plated back in the same media for 2–4 days. Organoids were subsequently switched to the DM differentiation media, composed as follows: AdDMEM/F12 medium (Life Technologies), 1% N2 and 1% B27 (Life Technologies), 50 ng/mL EGF (R&D Systems), 10 nM gastrin (Sigma), 25 ng/mL HGF (Miltenyi Biotec), 100 ng/mL FGF19 (R&D Systems), 500 nM A83.01 (Tocris), 10 μM DAPT (Sigma), 25 ng/mL BMP7 (Peprotech), and 30 μM Dexamethasone (Sigma).
+ Open protocol
+ Expand
9

Porcine ICO Differentiation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Prior to differentiation, porcine ICOs from 4 donors (n = 3 per donor) in the same passage number (p4) were cultured in EM with 25 ng/ml BMP7 (Peprotech) for 5 days. Differentiation medium (DM) was based on advanced DMEM/F12 (Life Technologies) containing 1% (v/v) Glutamax (Life Technologies), 1% (v/v) Penicillin–Streptomycin (Life Technologies), 1% (v/v) HEPES (Life Technologies), 1% (v/v) N2 (Invitrogen), 2% (v/v) B27 without vitamin A (Invitrogen), 1.25 mM N‐acetylcysteine (Sigma‐Aldrich), 5 μM A83‐01 (Tocris Bioscience), 50 ng/mL human epidermal growth factor (EGF, Invitrogen), 0.1 μg/ml human noggin (Peprotech), 0.1 μg/ml FGF19 (R&D Systems, Minneapolis, MN, USA), 10 nM gastrin (Sigma‐Aldrich), 25 ng/ml hepatocyte growth factor (HGF, Peprotech), 30 μM dexamethasone (Sigma‐Aldrich), 10 μM DAPT (y‐secretase inhibitor, Selleckchem), and 25 ng/ml BMP7 (Peprotech), and 1% (v/v) primocin (Gentaur, Kampenhout, Belgium). Differentiation medium was refreshed every 3 days until the end of differentiation culture (Day 5 and 9).
+ Open protocol
+ Expand
10

Western Blot and qRT-PCR Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were lysed for protein or RNA extraction, and subjected to western blot or cDNA synthesis and qRT-PCR was as previously described (24 (link)). Antibodies for western blot were as follows: β-Actin (Proteintech,66009-1-Ig), β-Tubulin (Proteintech, 66240-1-Ig), FGF19 (R&D System, AF969), FGFR4 (R&D System, MAB6852), FRS2 (Abcam, ab10425), pFRS2 (R&D System, AF5126), goat anti-mouse IgG-HRP (Jackson ImmunoResearch, 115-035-003), goat anti-rabbit IgG-HRP (Jackson ImmunoResearch, 111-035-003), donkey anti-Goat IgG-HRP (Sangon Biotech, D110115) and other antibodies were obtained from the Cell Signaling Technology. Primers for qPCR were as following: CCND1, forward 5′-GTCCTACTTCAAATGTGTGCAG-3′, reverse 5′-GGGATGGTCTCCTTCATCTTAG-3′; GAPDH forward 5′-GGAGCGAGATCCCTCCAAAAT-3′, reverse 5′-GGCTGTTGTCATACTTCTCATGG-3′.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!